The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

U.S. stocks closed higher on Thursday, with the S&P 500 reaching record highs after President Donald Trump ... on Friday ahead of its earnings before the opening bell. Analysts expect it to ...

Shares in the NYSE-listed company rose 77% at market open on 24 January 2025, compared to a market close, which occurred shortly after Allurion made the announcement. It is the highest price the ...

Allurion Technologies (NYSE:ALUR) climbed 200% in the morning hours on Friday, adding to its strong post-market gains yesterday, even after the weight loss product developer announced plans to ...

--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the ... The gross proceeds to the Company from this offering are expected to be approximately $7.4 million, before deducting the placement ...

Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its ...